生存期-话题@MedSci

#生存期#

350篇内容 | 3621人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1378189, encodeId=189313e81890b, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=NEJM：Durvalumab可显著延长III期非小细胞肺癌患者总生存期, objectType=article, longId=149667, objectId=310b14966e82, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=310b14966e82, replyNumber=0, likeNumber=88, createdTime=2018-09-28, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=310b14966e82, moduleTitle=NEJM：Durvalumab可显著延长III期非小细胞肺癌患者总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=310b14966e82)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378188, encodeId=9f0413e818870, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Lancet Oncol：曲妥珠单抗+帕妥珠单抗+化疗不能延长HER2阳性转移性胃或胃食管交界癌患者总生存期, objectType=article, longId=148716, objectId=1eac148e167e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1eac148e167e, replyNumber=0, likeNumber=57, createdTime=2018-09-14, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1eac148e167e, moduleTitle=Lancet Oncol：曲妥珠单抗+帕妥珠单抗+化疗不能延长HER2阳性转移性胃或胃食管交界癌患者总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1eac148e167e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378187, encodeId=ec0d13e818756, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=J Am Soc Nephrol：年龄和肾功能不同的晚期CKD老年患者，透析vs药物对生存期的影响, objectType=article, longId=148135, objectId=3cf714813501, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3cf714813501, replyNumber=0, likeNumber=101, createdTime=2018-09-05, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3cf714813501, moduleTitle=J Am Soc Nephrol：年龄和肾功能不同的晚期CKD老年患者，透析vs药物对生存期的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3cf714813501)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378186, encodeId=edb613e8186ab, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=PD-1抗体引起的不良反应预示着会有更长的生存期, objectType=article, longId=147516, objectId=5cee14e51627, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5cee14e51627, replyNumber=0, likeNumber=79, createdTime=2018-08-29, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5cee14e51627, moduleTitle=PD-1抗体引起的不良反应预示着会有更长的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5cee14e51627)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378185, encodeId=1dd413e8185bb, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=JAMA Pediatr：维持CDNS患儿无复发生存期：利妥昔单抗vs他克莫司, objectType=article, longId=146147, objectId=597c14614eb1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=597c14614eb1, replyNumber=0, likeNumber=79, createdTime=2018-08-10, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=597c14614eb1, moduleTitle=JAMA Pediatr：维持CDNS患儿无复发生存期：利妥昔单抗vs他克莫司, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=597c14614eb1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378184, encodeId=f65613e818483, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=PD-1单抗Keytruda单一疗法显著延长头颈癌患者生存期, objectType=article, longId=145228, objectId=52e21452281a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52e21452281a, replyNumber=0, likeNumber=87, createdTime=2018-07-28, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52e21452281a, moduleTitle=PD-1单抗Keytruda单一疗法显著延长头颈癌患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=52e21452281a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378183, encodeId=5e1a13e8183da, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Lancet Oncol：预测恶性肿瘤性胸腔积液患者生存期和胸膜固定术效果的标志物是, objectType=article, longId=144331, objectId=51d51443316a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51d51443316a, replyNumber=0, likeNumber=93, createdTime=2018-07-15, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51d51443316a, moduleTitle=Lancet Oncol：预测恶性肿瘤性胸腔积液患者生存期和胸膜固定术效果的标志物是, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=51d51443316a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378182, encodeId=735513e81824b, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=辉瑞的Ibrance在III期乳腺癌研究中未能显著延长生存期, objectType=article, longId=141716, objectId=f67b141e169c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f67b141e169c, replyNumber=0, likeNumber=69, createdTime=2018-06-28, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f67b141e169c, moduleTitle=辉瑞的Ibrance在III期乳腺癌研究中未能显著延长生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f67b141e169c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378181, encodeId=684f13e818121, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=JAMA oncology：晚期非小细胞肺癌局部放疗，生存期延长近3倍, objectType=article, longId=141647, objectId=f2a614164ebc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f2a614164ebc, replyNumber=0, likeNumber=70, createdTime=2018-06-27, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f2a614164ebc, moduleTitle=JAMA oncology：晚期非小细胞肺癌局部放疗，生存期延长近3倍, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f2a614164ebc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378180, encodeId=faf513e818049, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=JCO：达克替尼一线用于EGFR突变NSCLC患者，生存期达34.1个月（ARCHER 1050研究）, objectType=article, longId=141439, objectId=d96a141439e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d96a141439e2, replyNumber=0, likeNumber=75, createdTime=2018-06-25, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d96a141439e2, moduleTitle=JCO：达克替尼一线用于EGFR突变NSCLC患者，生存期达34.1个月（ARCHER 1050研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d96a141439e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378179, encodeId=66d813e81794e, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Lancet Neurol：雷沙吉兰可延缓ALS患者疾病进展但不能延长患者生存期, objectType=article, longId=141170, objectId=5a091411e0ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a091411e0ac, replyNumber=0, likeNumber=123, createdTime=2018-06-22, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a091411e0ac, moduleTitle=Lancet Neurol：雷沙吉兰可延缓ALS患者疾病进展但不能延长患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a091411e0ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378178, encodeId=815813e817808, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Nat Med:重大突破！PD-1竟可预测肺癌免疫治疗生存期！, objectType=article, longId=140950, objectId=2828140950dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2828140950dd, replyNumber=0, likeNumber=81, createdTime=2018-06-18, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2828140950dd, moduleTitle=Nat Med:重大突破！PD-1竟可预测肺癌免疫治疗生存期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2828140950dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378177, encodeId=fbad13e8177af, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Gastroenterology：mRNA125a、肿瘤免疫逃逸与食管腺癌患者生存期, objectType=article, longId=140350, objectId=60301403505e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=60301403505e, replyNumber=0, likeNumber=58, createdTime=2018-06-10, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=60301403505e, moduleTitle=Gastroenterology：mRNA125a、肿瘤免疫逃逸与食管腺癌患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=60301403505e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378176, encodeId=2fa013e81760e, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=JAMA：II-III期结肠癌患者术后CT及癌胚抗原筛查频率不影响患者生存期, objectType=article, longId=139025, objectId=24b2139025b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24b2139025b0, replyNumber=0, likeNumber=82, createdTime=2018-05-26, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24b2139025b0, moduleTitle=JAMA：II-III期结肠癌患者术后CT及癌胚抗原筛查频率不影响患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24b2139025b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378175, encodeId=073d13e8175e1, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Radiology：肝癌都这么大了，如何治疗才能提高生存期呢？, objectType=article, longId=138800, objectId=08af13880053, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08af13880053, replyNumber=0, likeNumber=72, createdTime=2018-05-23, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08af13880053, moduleTitle=Radiology：肝癌都这么大了，如何治疗才能提高生存期呢？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08af13880053)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378174, encodeId=451113e8174db, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=PLOS ONE：非小细胞肺腺癌生存期的不利独立预后指标, objectType=article, longId=137966, objectId=aa5213e96665, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa5213e96665, replyNumber=0, likeNumber=22, createdTime=2018-05-13, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa5213e96665, moduleTitle=PLOS ONE：非小细胞肺腺癌生存期的不利独立预后指标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa5213e96665)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378173, encodeId=590c13e817353, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Clin Transl Gastroenterol：血浆炎性细胞因子与胰腺癌患者的生存期相关, objectType=article, longId=137939, objectId=911c13e939d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=911c13e939d7, replyNumber=0, likeNumber=64, createdTime=2018-05-13, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=911c13e939d7, moduleTitle=Clin Transl Gastroenterol：血浆炎性细胞因子与胰腺癌患者的生存期相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=911c13e939d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378172, encodeId=fe8713e81729e, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Radiology：原来胶质母细胞瘤的肿瘤边缘规不规则能够提示术后生存期！, objectType=article, longId=137125, objectId=673013e1252c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=673013e1252c, replyNumber=0, likeNumber=89, createdTime=2018-05-04, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=673013e1252c, moduleTitle=Radiology：原来胶质母细胞瘤的肿瘤边缘规不规则能够提示术后生存期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=673013e1252c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378171, encodeId=a22513e81711e, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Cabozantinib与舒尼替尼作为中度或低风险转移性肾细胞癌的最佳治疗方案（Alliance A031203 CABOSUN随机试验）：总生存期和无进展生存, objectType=article, longId=136870, objectId=65ff1368e0d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65ff1368e0d9, replyNumber=0, likeNumber=111, createdTime=2018-05-01, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65ff1368e0d9, moduleTitle=Cabozantinib与舒尼替尼作为中度或低风险转移性肾细胞癌的最佳治疗方案（Alliance A031203 CABOSUN随机试验）：总生存期和无进展生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65ff1368e0d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378170, encodeId=546f13e817060, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Radiology：CT纹理指标能对肝癌晚期患者生存期提示点什么？, objectType=article, longId=136411, objectId=50d41364117f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50d41364117f, replyNumber=0, likeNumber=96, createdTime=2018-04-26, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50d41364117f, moduleTitle=Radiology：CT纹理指标能对肝癌晚期患者生存期提示点什么？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=50d41364117f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

生存期

2020-05-29

仁者大医 (审核中...)

前往app查看评论内容

#生存期#

NEJM：Durvalumab可显著延长III期非小细胞肺癌患者总生存期

2018-09-28

仁者大医 (审核中...)

前往app查看评论内容

#生存期#

Lancet Oncol：曲妥珠单抗+帕妥珠单抗+化疗不能延长HER2阳性转移性胃或胃食管交界癌患者总生存期

2018-09-14

仁者大医 (审核中...)

前往app查看评论内容

#生存期#

J Am Soc Nephrol：年龄和肾功能不同的晚期CKD老年患者，透析vs药物对生存期的影响

2018-09-05

仁者大医 (审核中...)

前往app查看评论内容

#生存期#

PD-1抗体引起的不良反应预示着会有更长的生存期

2018-08-29

仁者大医 (审核中...)

前往app查看评论内容

#生存期#

JAMA Pediatr：维持CDNS患儿无复发生存期：利妥昔单抗vs他克莫司

2018-08-10

仁者大医 (审核中...)

前往app查看评论内容

#生存期#

PD-1单抗Keytruda单一疗法显著延长头颈癌患者生存期

2018-07-28

仁者大医 (审核中...)

前往app查看评论内容

#生存期#

Lancet Oncol：预测恶性肿瘤性胸腔积液患者生存期和胸膜固定术效果的标志物是

2018-07-15

仁者大医 (审核中...)

前往app查看评论内容

#生存期#

辉瑞的Ibrance在III期乳腺癌研究中未能显著延长生存期

2018-06-28

仁者大医 (审核中...)

前往app查看评论内容

#生存期#

JAMA oncology：晚期非小细胞肺癌局部放疗，生存期延长近3倍

2018-06-27

仁者大医 (审核中...)

前往app查看评论内容

#生存期#

JCO：达克替尼一线用于EGFR突变NSCLC患者，生存期达34.1个月（ARCHER 1050研究）

2018-06-25

仁者大医 (审核中...)

前往app查看评论内容

#生存期#

Lancet Neurol：雷沙吉兰可延缓ALS患者疾病进展但不能延长患者生存期

2018-06-22

仁者大医 (审核中...)

前往app查看评论内容

#生存期#

Nat Med:重大突破！PD-1竟可预测肺癌免疫治疗生存期！

2018-06-18

仁者大医 (审核中...)

前往app查看评论内容

#生存期#

Gastroenterology：mRNA125a、肿瘤免疫逃逸与食管腺癌患者生存期

2018-06-10

仁者大医 (审核中...)

前往app查看评论内容

#生存期#

JAMA：II-III期结肠癌患者术后CT及癌胚抗原筛查频率不影响患者生存期

2018-05-26

仁者大医 (审核中...)

前往app查看评论内容

#生存期#

Radiology：肝癌都这么大了，如何治疗才能提高生存期呢？

2018-05-23

仁者大医 (审核中...)

前往app查看评论内容

#生存期#

PLOS ONE：非小细胞肺腺癌生存期的不利独立预后指标

2018-05-13

仁者大医 (审核中...)

前往app查看评论内容

#生存期#

Clin Transl Gastroenterol：血浆炎性细胞因子与胰腺癌患者的生存期相关

2018-05-13

仁者大医 (审核中...)

前往app查看评论内容

#生存期#

Radiology：原来胶质母细胞瘤的肿瘤边缘规不规则能够提示术后生存期！

2018-05-04

仁者大医 (审核中...)

前往app查看评论内容

#生存期#

Cabozantinib与舒尼替尼作为中度或低风险转移性肾细胞癌的最佳治疗方案（Alliance A031203 CABOSUN随机试验）：总生存期和无进展生存

2018-05-01

仁者大医 (审核中...)

前往app查看评论内容

#生存期#

Radiology：CT纹理指标能对肝癌晚期患者生存期提示点什么？

2018-04-26

科室
- - 订阅+
  - 更多科室
工具
服务